Singapore markets closed

VRTX Jan 2025 270.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
151.530.00 (0.00%)
At close: 03:46PM EDT
Full screen
Previous close151.53
Open151.53
Bid175.00
Ask185.00
Strike270.00
Expiry date2025-01-17
Day's range151.53 - 151.53
Contract rangeN/A
Volume1
Open interestN/A
  • Zacks

    Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex

    Vertex (VRTX) is set to acquire Alpine Immune Sciences (ALPN) for $65 per share in cash. The transaction is likely to close by second-quarter 2024.

  • Yahoo Finance Video

    Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal

    Vertex Pharmaceuticals (VRTX) is set to acquire Alpine Immune Sciences (APLN) for $4.9 billion in cash, gaining access to Alpine's treatments for kidney disease. The deal from Vertex values Alpine's stock at $65 a share, which is a nearly 67% premium from the stock's close on Tuesday. Yahoo Finance Anchors Josh Lipton and Julie Hyman discuss the trend of "pipeline in a product" deals. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino

  • Barrons.com

    Vertex Pharmaceuticals Seeks a Second Act With Alpine Immune Deal. What Wall Street Says.

    Vertex Pharmaceuticals is taking a big swing to secure its own second act: Late Wednesday, it announced a $4.9 billion deal to buy Alpine Immune Sciences which is developing a drug to treat a rare kidney disease. Vertex said it would pay $65 per share for Alpine, a 38.2% premium over the stock’s Wednesday closing price of $47.04. Shares of Alpine were trading at $64.19 early Thursday, while Vertex shares were up 1.2%.